ArticleClinical and vaccine immunology : CVI2008
Primary CD8+ T-cell response to soluble ovalbumin is improved by chloroquine treatment in vivo.
Article in Clinical and vaccine immunology : CVI, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 45 citations in OpenAlex.
- Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine.Clinical and vaccine immunology : CVI · 2014Trial
- NRGN inhibits CD8⁺ T cell effector function by downregulating MHC-I expression through the FMR1-IRF8 axis in hepatocellular carcinoma.Journal of experimental & clinical cancer research : CR · 2026Article
- Conformational stability of hemocyanins regulates their lysosomal and proteasomal degradation, influencing their pro-inflammatory effects on mammalian antigen-presenting cells.Frontiers in immunology · 2025Article
- Rationally designed catalytic nanoplatform for enhanced chemoimmunotherapy via deploying endogenous plus exogenous copper and remodeling tumor microenvironment.Journal of nanobiotechnology · 2024Article
- Nanoemulsions and nanocapsules as carriers for the development of intranasal mRNA vaccines.Drug delivery and translational research · 2024Article
- Thermogenic T cells: a cell therapy for obesity?American journal of physiology. Cell physiology · 2022Review
- Immunology of COVID-19: Current State of the Science.Immunity · 2020Review
- Rethinking the role of hydroxychloroquine in the treatment of COVID-19.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Review
- Engineering anti-cancer nanovaccine based on antigen cross-presentation.Bioscience reports · 2019Review
- Lymphocyte Autophagy in Homeostasis, Activation, and Inflammatory Diseases.Frontiers in immunology · 2018Review
- Recruitment of bone marrow CD11bScientific reports · 2017Article
- Article
- A plant-expressed conjugate vaccine breaks CD4(+) tolerance and induces potent immunity against metastatic Her2(+) breast cancer.Oncoimmunology · 2016Article
- In Vivo Synthesis of Cyclic-di-GMP Using a Recombinant Adenovirus Preferentially Improves Adaptive Immune Responses against Extracellular Antigens.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Spatial separation of the processing and MHC class I loading compartments for cross-presentation of the tumor-associated antigen HER2/Oncoimmunology · 2015Article
- Studying the effect of chloroquine on sporozoite-induced protection and immune responses in Plasmodium berghei malaria.Malaria journal · 2015Article
- Article
- Cross-presentation by dendritic cells.Nature reviews. Immunology · 2012Review
- Mechanism of immunopotentiation and safety of aluminum adjuvants.Frontiers in immunology · 2012Article
- Improved antigen cross-presentation by polyethyleneimine-based nanoparticles.International journal of nanomedicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The efficiency of cross-presentation of exogenous antigens by dendritic cells (DCs) would seem to be related to the level of antigen escape from massive degradation mediated by lysosomal proteases in an acidic environment. Here, we demonstrate that a short course of treatment with chloroquine in mice during primary immunization with soluble antigens improved the cross-priming of naïve CD8(+) T lymphocytes in vivo. More specifically, priming of chloroquine-treated mice with soluble ovalbumin (OVA), OVA associated with alum, or OVA pulsed on DCs was more effective in inducing OVA-specific CD8(+) T lymphocytes than was priming of untreated mice. We conclude that chloroquine treatment improves the cross-presentation capacity of DCs and thus the size of effector and memory CD8(+) T cells during vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.